Combined with TCGA database to explore the results of EGFR gene mutation in NSCLC patients and its clinical significance

Objective To obtain data results from the cancer genome altas (TCGA) database and analyze the correlation between clinical features and prognosis of patients with non-small cell lung cancer (NSCLC) and the types of hotspot driver mutations.

Methods The clinical data of 115 hospitalized patients with NSCLC (NSCLC group) were retrospectively analyzed.Gene mutation was detected by second-generation high-throughput sequencing, and the clinical data and gene mutation data of NSCLC were obtained by combining TCGA database to analyze the relationship between gene mutation and patient prognosis.

Results High-throughput sequencing results showed that the total gene mutation rate of NSCLC patients was 76.52% (88/115), and the human epidermal growth factor receptor (EGFR) mutation rate was 53.91% (62/115).The total mutation rate of genes in TCGA database was 93.57%, and the mutation rate of EGFR gene was only 7%.There was significant difference between NSCLC patients with EGFR unit point mutation and co-mutation in whether distant metastasis occurred (P < 0.05).The results of multi-factor analysis showed that the number of gene mutations was an independent risk factor affecting the prognosis of patients (P < 0.05).

Conclusions EGFR point mutation and co-mutation have a certain effect on the prognosis of NSCLC patients, and patients with polygenic co-mutation have a better prognosis, and clinical treatment should pay attention to the situation of gene co-mutation.